Compare
Gilead Sciences vs Krystal Biotech (GILD vs KRYS)
The two stocks side by side, as of the latest close. Performance is rebased to 100 at the start of the window.
Over the past year Gilead Sciences (GILD) returned +36.1% and Krystal Biotech (KRYS) +50.5%; so far this year the figures are +36.0% and +22.0%.
Gilead Sciences is the larger company by market value, about 23.2 times the size of Krystal Biotech.
Revenue grew +6.5% at GILD and +26.0% at KRYS over the last year.
GILD yields 1.95%. KRYS pays no dividend.
Data as of the latest close. Not investment advice.
Relative performance
| GILD | KRYS | |
|---|---|---|
| Price | $166.89 | $300.88 |
| 1-day | -0.41% | +0.21% |
| YTD | +35.97% | +22.04% |
| 1 year | +36.15% | +50.53% |
| 3 years | +108.12% | +152.18% |
| Market cap | $207.0B | $8.9B |
| P/E | — | 40.8 |
| P/S | 6.68 | 18.97 |
| P/B | 15.87 | 6.21 |
| Revenue growth | +6.50% | +26.00% |
| EPS growth | -149.00% | +10.30% |
| Gross margin % | 79.9 | — |
| Net margin % | -12.5 | 47.9 |
| ROE % | -29.6 | 15.7 |
| Debt / equity | 2.01 | 0.00 |
| FCF yield % | 6.7 | 3.5 |
| Dividend yield % | 1.95 | — |
| Beta | 0.37 | 0.75 |
| RSI (14) | 60.2 | 39.9 |
| Technical rating |